Have you ever thought about banking your pet’s stem cells the same way people bank cord blood for newborns? It sounds futuristic, right? But Gallant is making that exact idea a reality. This company stepped into the Shark Tank spotlight with a pitch that left the sharks genuinely intrigued. And years later, people are still searching for updates. So let’s break it all down for you, from the original pitch to where Gallant stands today in 2026.
Gallant Details
Gallant is a pet healthcare startup built around one powerful idea. When your dog or cat goes in for a routine spay or neuter procedure, the reproductive tissue that gets removed is typically discarded. Gallant saw something different in that tissue. They saw stem cells.
The company collects those stem cells during the procedure, processes them, and stores them cryogenically for future use. Think of it as a biological insurance policy for your pet. If your furry companion develops arthritis, joint issues, or other degenerative conditions down the road, those stored stem cells could be used in regenerative veterinary medicine to help treat them.
The founder, Aaron Hirschhorn, built Gallant on the belief that pet owners deserve access to the same kind of cutting-edge medical options that exist in human healthcare. And honestly, that belief resonates. Pet owners today spend billions on animal healthcare every year. The demand for innovative veterinary services is real and growing fast.
Gallant’s service works through veterinary clinic partnerships. When a vet performs a spay or neuter, they use Gallant’s stem cell collection kits to gather the tissue. It gets shipped to an FDA-registered facility where it’s processed and stored using cryogenic stem cell preservation techniques. The cost at launch was around $400 for collection and processing, plus an annual storage fee.
It’s a clean, simple model. And it taps directly into the emotional bond people have with their pets.
Shark Tank Episode Details
Gallant appeared on Shark Tank Season 11, Episode 8. The episode aired in November 2019. Aaron Hirschhorn walked into the tank seeking $500,000 in exchange for 5% equity. That valuation, $10 million, was bold for a company at that stage.
The sharks on the panel included Lori Greiner, Kevin O’Leary, Mark Cuban, and guest shark Anne Wojcicki, who is the co-founder of the genetic testing company 23andMe. That last detail matters a lot. Anne brought a unique lens to this pitch because she deeply understands the science behind regenerative medicine and genomic health. Her presence in the room was almost tailor-made for a pitch like Gallant’s.
Read More: Balm Chicky Balm Balm – Shark Tank Update 2026
The Shark Tank Pitch
Aaron walked in calm and confident. He laid out the concept clearly. Every year, millions of spay and neuter procedures happen across the United States. All that tissue gets thrown away. Gallant’s pitch was simple: stop throwing away something valuable.
He explained the pet stem cell therapy process in plain terms. No confusing jargon. Just a clear story about giving pet owners a future treatment option by saving something that would otherwise go in the trash.
The sharks responded with curiosity. Anne Wojcicki was visibly engaged. She asked smart, science-forward questions and clearly understood the potential of stem cell banking for pets. Lori Greiner, always sharp on market potential, saw the emotional hook clearly. Pet owners are passionate. They’re loyal buyers. And they will absolutely spend money on something that could extend or improve their pet’s life.
Kevin O’Leary pushed on the numbers, as he always does. He wanted to understand the path to profitability and the scalability of veterinary clinic partnerships. Mark Cuban questioned the regulatory landscape and the timeline for getting stem cell therapy for pet arthritis and other conditions commercially approved.
In the end, Anne Wojcicki and Lori Greiner teamed up and made an offer. They came in together at $500,000 for 10% equity. Aaron had to give up more than he originally wanted, but he accepted the deal. It was a pivotal moment. Having Anne Wojcicki, someone with deep roots in science and health technology, on board was worth the extra equity.
The deal made sense on every level. Two sharp investors, one with a science background and one with a consumer products background, backing a pet medical technology company. It felt like a strong match.
Where Are They Now?
This is the part everyone wants to know. So what actually happened after the cameras stopped rolling?
Gallant continued building out its veterinary partnership program after the show. The company expanded its network of partner clinics and kept refining the stem cell collection kits to make the process easier for veterinary professionals. The pitch had given them national visibility, and they used it.
By 2024, Gallant had secured Series A funding to push its growth further. That round of investment signaled real confidence from the broader investment community in the future of pet regenerative medicine. They weren’t just a Shark Tank story anymore. They were becoming a serious player in the pet health investment space.
In 2025 and moving into 2026, the conversation around stem cell therapy commercialization has grown louder. More veterinary clinics are open to regenerative treatment for animals than ever before. Research into animal stem cell research has advanced, and the public awareness around pet wellness technology has expanded significantly.
Gallant has positioned itself well in this shifting landscape. The company continues to focus on pet lifespan extension through stored biological material and aims to bring actual treatment options to market as regulatory pathways become clearer.
The honest reality is that stem cell therapy for pets is still developing. Not every stored sample will be used. The science is promising but not fully commercialized at scale yet. However, Gallant’s value isn’t just in treatment today. It’s in readiness. Banking now means having options later.
If you’re a pet owner who has a young dog or cat scheduled for a spay or neuter, Gallant is genuinely worth looking into. The window for collection is narrow. It only happens during that one procedure. Once it’s done, the opportunity is gone.
That’s not a scare tactic. That’s just biology.
FAQ’s
What is Gallant and what does it do?
Gallant is a pet stem cell banking company that collects and stores stem cells from spay and neuter procedures for potential future regenerative treatments.
Did Gallant get a deal on Shark Tank?
Yes, Aaron Hirschhorn accepted a deal from Anne Wojcicki and Lori Greiner for $500,000 in exchange for 10% equity during Season 11.
Is Gallant still operating in 2026?
Yes, Gallant is still active and has continued expanding its veterinary partnerships and secured Series A funding to support its growth.
How much does Gallant’s stem cell banking service cost?
At launch, the service was priced around $400 for collection and processing, with an additional annual storage fee for ongoing cryogenic preservation.
Can stored stem cells actually help treat my pet?
The science is promising, particularly for conditions like arthritis and joint degeneration, though full commercial treatment options are still developing as regulatory approvals progress.
Ryan Mitchell is a seasoned digital marketing strategist and content writer with over 8 years of experience in SEO and guest posting. He has contributed to top business publications, helping brands grow their online visibility through data-driven strategies. Ryan focuses on ethical link building and sustainable content growth practices.